Pulmonary Involvement of Diffuse Large B-cell Lymphoma with Cavitary Lesions

Abstract Diffuse large B-cell lymphoma (DLBCL) is the most common type of extranodal lymphoma. Typically disease occurs fastly growing nodal or extranodal masses with systemic symptoms. Pulmonary involvement may also occur in DLBCL. Here we present a DLBCL with cavitary lesions in the lung. A 59-year-old male was diagnosed with DLBCL through an endoscopic gastric biopsy that was performed 1.5 years ago. After six course of R-CHOP chemotherapy, the relaps of disease was confirmed with mediastinoscopy. Despite two courses of RICE chemotherapy and one course of R-BAB therapies, the patient was admitted to the intensive care unit with shortness of breath and tachypnea. Thorax computed tomography showed a mass lesion that enclosed and narrowed the right major bronchus and multiple lesions with cavitation. The infections were excluded with bronchoscopy. The patient received pulse steroid therapy, radiotherapy and three courses of Hyper-CVAD chemotherapy. In the control thorax CT, cavitary lesions got smaller, respiratory insufficiency of patient improved. When pulmonary cavitary lesions are observed in patients under follow-up with the diagnosis of lymphoma, the pulmonary involvement of lymphoma should also be considered in addition to the infectious agents

Impact of prior JAK-inhibitor therapy with ruxolitinib on outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis: a study of the CMWP of EBMT.

JAK1/2 inhibitor ruxolitinib (RUX) is approved in patients with myelofibrosis but the impact of pretreatment with RUX on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) remains to be determined. We evaluated the impact of RUX on outcome in 551 myelofibrosis patients who received HSCT without (n = 274) or with (n = 277) RUX pretreatment. The overall leukocyte engraftment on day 45 was 92% and significantly higher in RUX responsive patients than those who had no or lost response to RUX (94% vs. 85%, p = 0.05). The 1-year non-relapse mortality was 22% without significant difference between the arms. In a multivariate analysis (MVA) RUX pretreated patients with ongoing spleen response at transplant had a significantly lower risk of relapse (8.1% vs. 19.1%; p = 0.04)] and better 2-year event-free survival (68.9% vs. 53.7%; p = 0.02) in comparison to patients without RUX pretreatment. For overall survival the only significant factors were age > 58 years (p = 0.03) and HLA mismatch donor (p = 0.001). RUX prior to HSCT did not negatively impact outcome after transplantation and patients with ongoing spleen response at time of transplantation had best outcome

Hepatitis B-related events in autologous hematopoietic stem cell transplantation recipients

AIM: To investigate the frequency of occult hepatitis B, the clinical course of hepatitis B virus (HBV) reactivation and reverse seroconversion and associated risk factors in autologous hematopoietic stem cell transplantation (HSCT) recipients

Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels?

Chemo/radiotherapy-induced free oxygen radicals and reactive oxygen derivatives contribute to the development of early and late transplantation-related pulmonary and extra-pulmonary complications in hematopoietic stem cell transplantation (HSCT) recipients. It has been proposed that an increase in fractional exhaled nitric oxide (FeNO) level indicates oxidative stress and inflammation in the airways. The aim of this prospective study is to evaluate the pre-transplantation FeNO levels in HSCT patients and to search for its role in predicting post-transplantation pulmonary complications and mortality

A new hope in the treatment of steroid-refractory graft versus host disease (Sr-GVHD) after allogeneic hematopoetic stem cell transplantation (AHSCT): Ruxolitinib

..